Table 1.
Baseline characteristics of patients with grade 0-II and grade III–IV acute graft-versus-host disease.
| Variable | Grade 0-II aGVHD (n=53) | Grade III–IV aGVHD (n=18) | P value |
|---|---|---|---|
| Recipient age in years, median (range) | 3.58 (0.67–12.57) | 3.98 (1.42–8.83) | 0.463 |
| Sex | 0.634 | ||
| Male, n (%) | 27 (51%) | 8 (44%) | |
| Female, n (%) | 26 (49%) | 10 (56%) | |
| Disease | 0.053 | ||
| AML, n (%) | 30 (57%) | 8 (44%) | |
| ALL, n (%) | 23 (43%) | 8 (44%) | |
| MAL, n (%) | 0 (0%) | 2 (12%) | |
| HLA matching | 0.076 | ||
| ≥9/10, n (%) | 36 (68%) | 8 (44%) | |
| <9/10, n (%) | 17 (32%) | 10 (56%) | |
| ABO matching | 0.663 | ||
| Matched, n (%) | 12 (23%) | 5 (28%) | |
| Mismatched, n (%) | 41 (77%) | 13 (72%) | |
| Disease status at transplant | 0.405 | ||
| CR1, n (%) | 32 (60%) | 13 (72%) | |
| CR2, n (%) | 11 (21%) | 2 (11%) | |
| PR, n (%) | 7 (13%) | 3 (17%) | |
| NR, n (%) | 3 (6%) | 0 (0%) | |
| Conditioning intensity | 0.037 | ||
| MAC, n (%) | 43 (81%) | 10 (56%) | |
| RIC, n (%) | 10 (19%) | 8 (44%) | |
| ATG | 0.340 | ||
| Yes, n (%) | 11 (21%) | 2 (11%) | |
| No, n (%) | 42 (79%) | 16 (89%) | |
| Conditioning drug dose median (range) | |||
| Bu, mg/kg | 12.31 (8.64–14.20) | 12.80 (8.40–14.10) | 0.450 |
| CTX, mg/kg | 120.00 (75.79–141.00) | 120.00 (72.00–141.18) | 0.317 |
| Neutrophil engraftment time, median (range), days | 15.00 (10.00–29.00) | 15.00 (12.00–23.00) | 0.680 |
| Platelet engraftment time, median (range), days | 31.00 (13.00–43.00) | 27.50 (11.00–56.00) | 0.277 |
| Total infused cell count, median (range) | |||
| MNC, ×107/kg | 6.20 (1.30–11.33) | 5.90 (1.37–11.79) | 0.895 |
| CD34+, ×105/kg | 2.73 (1.70–6.41) | 2.78 (0.83–9.20) | 0.648 |
| SF level within 2 weeks post-transplant | 0.022 | ||
| >1650 ng/mL, n (%) | 28 (53%) | 15 (83%) | |
| <1650 ng/mL, n (%) | 25 (47%) | 3 (17%) | |
| SF level within 2 weeks pretransplant | 0.251 | ||
| >1650 ng/mL, n (%) | 6 (11%) | 4 (22%) | |
| <1650 ng/mL, n (%) | 47 (89%) | 14 (78%) |
aGVHD – acute graft-versus-host disease; ALL – acute lymphocytic leukemia; AML – acute myeloid leukemia; ATG – anti-thymocyte globulin; Bu – busulfan; CI – confidence interval; CR – complete response; CTX – cyclophosphamide; HR – hazard ratio; MAL – mixed phenotype acute leukemia; MNC – mononuclear cells; NR – no response; PR – partial response; SF – serum ferritin.